Results for "consumer data right"
641-650 of 843 results for 'consumer data right'
New 12th edition Nice Classification comes into force 1 January 2023
The World Intellectual Property Organization (WIPO) has announced that the 12th edition of the Nice Classification – the international system for classifying goods and services for registering trade marks – will come into force in the new year, on 1 January 2023. ...
Important developments for offshore diagnostic testing
In Ariosa Diagnostics, Inc & Ors v Sequenom, Inc [2021] FCAFC 101, the Full Federal Court delivered significant clarity for companies who provide or conduct diagnostic tests. ...
The interim report of the Financial System Inquiry
The Financial System Inquiry Interim Report was issued today There are few surprises in the options and comments although there are some significant omissions There does not appear to be any push for a significant shift in policy or in the regulation of the financial system There will be adjustments ...
The mRNA rush
There is great potential for mRNA technology to revolutionise future vaccines, and treatment of various conditions such as rare genetic disorders, other infectious diseases and even cancer. The enthusiasm for the technology – or the 'mRNA rush' – is reflected by a spike in patent filings over the past five years, and the growing patent portfolios of key mRNA pioneers and market players. ...
New .au direct domain names available for registration from 24 March 2022
Further to our last update, new .au direct domain names (eg 'allens.au' instead of 'allens.com.au') have officially launched today. Eligible applicants will have a six month window to apply for priority status to register a .au direct domain name that matches their existing .au domain name. ...
InIP: What's happening in intellectual property - April 2023
Your regular wrap-up of some of the world's leading and intriguing IP stories. ...
Down-scheduling CBD and growing Australia's cannabis industry
The Therapeutics Goods Administration is proposing amendments to the Poisons Standard to permit pharmacists to sell low-dose cannabidiol (CBD) products without a prescription. Businesses intending to import, manufacture and supply cannabis products in the Australian market should monitor these developments closely. ...
Final report on review of Australia’s patent system
The Federal Government has released the final report on the review of the accessibility of patents for small and medium sized enterprises (SMEs), which follows the phasing-out of the innovation patent system in Australia. ...
Swiss claims and skinny labels: Full Federal Court considers infringement
An enlarged bench of the Full Federal Court has considered the principles applying to infringement of Swiss-style claims, with the decision potentially limiting the application of Swiss-style claims in the context of so-called second medical use patents, where the allegedly infringing products are ʽskinny-labelled’. ...